Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Novartis patent term dabrafenib?Diltiazem drug class?Abbvie humira patent cliff navigation success?Patent expiration eu dabrafenib?Lipitor vs generics what's the price gap?
See the DrugPatentWatch profile for wegovy
Wegovy and Ozempic both contain semaglutide as their active ingredient. Semaglutide is a GLP-1 receptor agonist that mimics a hormone to regulate blood sugar, slow gastric emptying, and reduce appetite.[1]
Despite sharing semaglutide, they are formulated for different uses and doses: - Ozempic: Approved for type 2 diabetes management; weekly doses up to 2 mg semaglutide. - Wegovy: Approved for chronic weight management; higher weekly doses up to 2.4 mg semaglutide. Inactive ingredients are similar but vary slightly by dose and pen design, including disodium phosphate dihydrate, propylene glycol, phenol, and water for injection.[1][2]
Novo Nordisk manufactures both under separate FDA approvals. Semaglutide's patents protect the molecule until around 2031-2033 in the US, delaying generics.[3] No generics exist yet.
Patients often ask if ingredients cause allergies—phenol acts as a preservative, and propylene glycol may trigger rare reactions. Semaglutide itself rarely causes hypersensitivity.[1][2] [1]: Novo Nordisk Wegovy Prescribing Information [2]: Novo Nordisk Ozempic Prescribing Information [3]: DrugPatentWatch.com - Semaglutide Patents
Other Questions About Wegovy :